Testosterone Enanthate and Sildenafil Interaction: What Clinicians and Patients Need to Know

What Is the Core Interaction Between Testosterone Enanthate and Sildenafil?

The combination carries a pharmacodynamic interaction, not a major pharmacokinetic one. Both agents can lower systemic vascular resistance through independent mechanisms, and their co-administration in men with cardiovascular disease or polypharmacy may produce additive hypotension. Neither agent meaningfully inhibits or induces the other's primary metabolic enzyme at clinical doses.

Mechanism of Testosterone Enanthate

Testosterone enanthate is an esterified androgen injected intramuscularly. After injection, ester hydrolysis releases free testosterone into circulation. Testosterone and its active metabolite dihydrotestosterone (DHT) act on androgen receptors in vascular smooth muscle, promoting vasodilation and, at physiologic concentrations, modest reductions in peripheral vascular resistance. A 2019 meta-analysis in the Journal of Clinical Endocrinology & Metabolism (N=1,981 pooled participants) found that testosterone replacement produced a mean systolic blood pressure reduction of 2.0 mmHg compared with placebo, a modest but real hemodynamic effect. [1]

Testosterone is metabolized primarily via CYP3A4 in the liver, with minor contributions from CYP2C19. The FDA label for testosterone enanthate (Delatestryl) identifies CYP3A4 as the principal metabolic route. [2]

Mechanism of Sildenafil

Sildenafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. Elevated cGMP causes smooth muscle relaxation and vasodilation in the penile corpus cavernosum and, to a lesser extent, systemic vasculature. The FDA label for sildenafil (Viagra) reports a mean maximum decrease in supine systolic blood pressure of 8.4 mmHg and diastolic pressure of 5.5 mmHg after a 100 mg oral dose in healthy men. [3] Sildenafil is metabolized predominantly by CYP3A4 (major) and CYP2C9 (minor), producing an active metabolite (N-desmethyl sildenafil) via CYP3A4.

Where the Two Pathways Converge

Both drugs use CYP3A4 for metabolism. At standard clinical doses, competitive inhibition between the two at CYP3A4 is not considered clinically significant in current DDI databases. However, potent CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) added to this combination could raise sildenafil exposure substantially. Coadministration of ritonavir 500 mg twice daily with sildenafil increased sildenafil AUC by 1,000% according to the sildenafil FDA label. [3] That is an extreme example, but it illustrates how third-drug interactions can transform a low-risk combination into a high-risk one.

Severity Classification and Clinical Significance

Drug interaction databases classify the testosterone enanthate plus sildenafil pairing as a minor to moderate interaction in most patients, escalating to clinically significant in men with heart failure, uncontrolled hypertension, or concomitant nitrate therapy. The American Urological Association (AUA) 2018 Erectile Dysfunction Guideline (updated 2024) states: "PDE5 inhibitors are contraindicated in men taking any form of nitrate therapy and should be used with caution in men with significant cardiovascular disease." [4]

The Nitrate Rule

This is the hard stop. If a patient on testosterone enanthate also takes any nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) for angina or heart failure, sildenafil is absolutely contraindicated. Nitrates and PDE5 inhibitors share a downstream cGMP pathway, and their combination can cause severe, potentially fatal hypotension. A pharmacodynamic study published in the Journal of the American College of Cardiology (N=18) documented a mean systolic blood pressure drop of 36 to 52 mmHg when sildenafil 100 mg was combined with sublingual nitroglycerin 0.4 mg. [5] Testosterone enanthate does not directly amplify this interaction, but a prescriber evaluating the full medication list must identify all three agents.

Cardiovascular Risk Stratification

The Princeton III Consensus (2012), updated recommendations from cardiovascular societies, categorizes sexual activity and PDE5 inhibitor use by cardiac risk tier. Men on testosterone replacement who fall into the intermediate or high cardiac risk tier (recent myocardial infarction within 6 weeks, unstable angina, New York Heart Association Class III or IV heart failure, uncontrolled arrhythmia, or resting BP above 170/100 mmHg) require cardiology evaluation before sildenafil is added. The Princeton III panel published its recommendations in the Journal of Sexual Medicine and explicitly addressed TRT patients, noting that testosterone optimization may reduce cardiovascular risk factors but does not independently clear a patient for PDE5 inhibitor use. [6]

Pharmacokinetic Details: Does Testosterone Enanthate Change Sildenafil Exposure?

At steady-state testosterone concentrations achieved with standard TRT dosing (targeting total testosterone 400 to 700 ng/dL per most guidelines), there is no documented inhibition or induction of CYP3A4 that would alter sildenafil plasma concentrations in a meaningful way. The Endocrine Society 2018 Clinical Practice Guideline recommends targeting a morning total testosterone of 400 to 700 ng/dL for most hypogonadal men, using the lowest effective dose of the chosen formulation. [7]

Polycythemia as an Indirect Risk Factor

Testosterone enanthate raises erythropoiesis. Hematocrit rises of 3 to 6 percentage points above baseline are common, and values exceeding 54% may increase blood viscosity and thrombotic risk. A 2023 randomized controlled trial, the TRAVERSE study (N=5,246), published in the New England Journal of Medicine, found that testosterone therapy produced higher rates of pulmonary embolism (0.9% vs. 0.5%) and hematocrit elevation compared with placebo in men with hypogonadism and cardiovascular risk factors. [8] In men with elevated hematocrit, the vasodilatory effect of sildenafil could theoretically worsen symptoms of hyperviscosity-related cardiovascular strain, though direct evidence for this specific combination is limited.

Protein Binding Considerations

Testosterone binds heavily to sex hormone-binding globulin (SHBG) and albumin, leaving approximately 2 to 3% as free testosterone. Sildenafil is 96% protein-bound, primarily to albumin. At therapeutic doses, displacement interactions at albumin binding sites are not expected to be clinically significant for either drug, as neither is a narrow therapeutic index agent with respect to protein binding.

Who Is at Highest Risk From This Combination?

Not every man on testosterone enanthate who takes sildenafil requires special precautions beyond standard PDE5 inhibitor counseling. Risk is concentrated in specific subgroups.

High-Risk Subgroups

Men with any of the following characteristics warrant closer evaluation before combining these agents:

• Resting systolic BP below 90 mmHg or above 170 mmHg
• Known coronary artery disease, prior MI, or coronary stent placed within 6 months
• New York Heart Association Class II or higher heart failure
• Concurrent use of alpha-blockers (tamsulosin, doxazosin, terazosin) for benign prostatic hyperplasia, which independently lower BP and can compound hypotension when sildenafil is added
• Any nitrate use (as described above, absolute contraindication)
• Hematocrit above 52% from testosterone-driven polycythemia

The sildenafil FDA label specifically warns: "The co-administration of the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg) was associated with significant reductions in blood pressure in patients with benign prostatic hyperplasia." [3] Men on TRT who are also taking alpha-blockers for lower urinary tract symptoms represent a particularly common and underappreciated overlap scenario.

The Alpha-Blocker Triangle

A man on testosterone enanthate for hypogonadism, tamsulosin 0.4 mg for BPH, and sildenafil 50 mg for erectile dysfunction has three agents that can each lower blood pressure through distinct mechanisms. Separating tamsulosin and sildenafil administration by at least 4 hours is the standard guidance from the sildenafil FDA label, and the patient's testosterone injection schedule should be considered when timing sildenafil relative to peak androgen levels.

Dose Adjustment and Prescribing Guidance

No mandatory dose adjustment of testosterone enanthate is required specifically because of sildenafil co-prescribing. The reverse is also true as a general rule. Practical guidance follows standard prescribing parameters.

Sildenafil Starting Dose in TRT Patients

Begin at 25 to 50 mg orally approximately one hour before anticipated sexual activity. The AUA Erectile Dysfunction Guideline recommends starting PDE5 inhibitors at the lowest approved dose in men with cardiovascular comorbidities and titrating based on response and tolerability. [4] Dose escalation to 100 mg may be considered if 50 mg is tolerated without significant blood pressure reduction.

Testosterone Enanthate Dosing Range

The FDA-approved dosing range for testosterone enanthate in male hypogonadism is 50 to 400 mg administered intramuscularly every 2 to 4 weeks. [2] Most contemporary TRT protocols use 100 to 200 mg every 1 to 2 weeks to produce steadier serum testosterone levels and avoid the supraphysiologic spikes associated with longer intervals. Steady-state serum testosterone is relevant to sildenafil co-prescribing because supratherapeutic testosterone levels (above 1,050 ng/dL) may exacerbate erythrocytosis and cardiovascular risk.

Monitoring Protocol

A practical monitoring framework for men co-prescribed testosterone enanthate and sildenafil:

| Parameter | Frequency | Target or Action Threshold | |---|---|---| | Seated blood pressure | At each TRT follow-up and before sildenafil dose titration | Below 130/80 mmHg; hold sildenafil if systolic <90 mmHg | | Hematocrit / hemoglobin | Every 3 to 6 months on TRT | Hematocrit <54%; reduce TRT dose or phlebotomize if exceeded | | Total testosterone | 6 to 8 weeks after dose change | Target 400 to 700 ng/dL (morning trough or midpoint) | | Lipid panel | Annually | Monitor for TRT-related HDL reduction | | Symptoms of hypotension | Every visit | Dizziness, syncope, chest discomfort prompt immediate evaluation |

Patient Counseling Points

Clear communication with the patient reduces the risk of adverse events that are preventable.

What to Tell Patients Before They Leave the Office

Patients should understand that taking sildenafil on the same day as a testosterone enanthate injection is generally acceptable but warrants self-monitoring for dizziness, lightheadedness, or palpitations in the 4 to 6 hours after either administration, particularly on the first occasion. They should not combine sildenafil with any nitrate medication, including recreational amyl nitrite (poppers). The sildenafil FDA label states that co-administration with organic nitrates of any form is contraindicated because of the risk of profound hypotension. [3]

Patients should also know that alcohol consumption above two standard drinks can add to the hypotensive effect of sildenafil. Combined with the mild vasodilatory contribution of testosterone, this creates a setting where symptomatic hypotension becomes more likely, especially in older men or those who are volume-depleted.

Reporting Symptoms

Any chest pain occurring within 24 hours of sildenafil use requires emergency evaluation and the treating team must be told that sildenafil was taken before any nitrate is administered in the emergency setting. This is a potentially life-saving counseling point that is often omitted in routine TRT prescribing.

Testosterone Enanthate and Other Drug Interactions Relevant to This Context

Men on TRT frequently carry multiple prescriptions. Broader interaction awareness is part of safe TRT management.

Anticoagulants

The testosterone enanthate FDA label carries a warning that androgens may increase sensitivity to oral anticoagulants, requiring more frequent INR monitoring when warfarin or other vitamin K antagonists are co-prescribed. [2] This is a separate interaction from sildenafil but is relevant in men with atrial fibrillation, who may be on both anticoagulants and TRT.

Insulin and Oral Hypoglycemics

Testosterone improves insulin sensitivity in hypogonadal men. The TRAVERSE trial (N=5,246) showed that testosterone therapy reduced the incidence of new-onset type 2 diabetes by 12% compared with placebo over a median 33-month follow-up. [8] Men on insulin or sulfonylureas who begin TRT may require downward dose adjustments of their antidiabetic agents to avoid hypoglycemia. Sildenafil does not directly affect glucose metabolism, but hypoglycemia itself causes catecholamine release and blood pressure shifts that could interact with sildenafil's hemodynamic effects in a clinical setting.

CYP3A4 Inhibitors and Inducers

Because sildenafil is a CYP3A4 substrate, any potent CYP3A4 inhibitor added to a regimen containing both testosterone enanthate and sildenafil deserves attention. Common offenders include azole antifungals (fluconazole, itraconazole), macrolide antibiotics (erythromycin, clarithromycin), and HIV protease inhibitors. When any of these is prescribed, the sildenafil dose should be reduced to 25 mg and the patient should be counseled about enhanced hypotension risk.

Regulatory and Guideline Summary

The Endocrine Society 2018 Testosterone Therapy Clinical Practice Guideline recommends against prescribing testosterone therapy to men with uncontrolled heart failure, recent cardiovascular events within 3 to 6 months, or untreated sleep apnea. [7] These same conditions are relative or absolute contraindications to sildenafil in the context of cardiovascular risk. Men who meet any of these criteria and are prescribed both agents need cardiology clearance before proceeding.

A 2022 systematic review in JAMA Internal Medicine (N=4,421 from 11 randomized trials) concluded that testosterone therapy produced statistically significant improvements in erectile function scores (mean IIEF-EF domain improvement of 2.3 points) but did not eliminate the need for PDE5 inhibitors in a substantial proportion of hypogonadal men. [9] This finding supports the clinical reality that co-prescribing TRT and sildenafil is common and, in appropriately selected patients, appropriate.